Therapeutic uses of allogeneic myeloid progenitor cells

Patent metadata

Field	Value
Publication number	US-8980329-B2
Application number	US-87502210-A
Country	US
Kind code	B2
Filing date	Sep 2, 2010
Priority date	Nov 15, 2004
Publication date	Mar 17, 2015
Grant date	Mar 17, 2015

Abstract

Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

First claim

What is claimed is:

1. A method of providing myeloid function in a individual in need thereof, said method comprising:
transplanting into said individual a biologically effective dose of allogeneic myeloid progenitor cells.

2. The method according to claim 1 , wherein said myeloid progenitor cells comprise at least one Class I HLA mismatch relative to said individual.

3. The method according to claim 1 , wherein said allogeneic myeloid progenitor cells are common myeloid progenitor (CMP) cells.

4. The method according to claim 2 , wherein said allogeneic myeloid progenitor cells further comprise granulocyte/monocyte progenitors (GMP).

5. The method according to claim 1 , further comprising the administration of G-CSF to said individual.

6. The method according to claim 1 , further comprising the step of: administering GM-CSF to said individual.

7. The method according to claim 1 , further comprising the administration of an anti-fungal or antibacterial agent to said individual.

8. The method according to claim 3 , wherein said allogeneic myeloid progenitor cells further comprise myeloid erythroid progenitors (MEP).

9. The method according to claim 8 , further comprising the step of: administering erythropoietin to said individual.

10. The method according to claim 3 , wherein said allogeneic myeloid progenitor cells further comprise megakaryocyte progenitors (MKP).

11. The method according to claim 10 , further comprising the step of: administering thrombopoietin to said individual.

12. The method according to claim 1 ,
wherein said cells are enriched prior to said transplanting step by the method of combining reagents that specifically recognize Thy-1, IL-7Rα (CD127), and a lineage panel with a sample of hematopoietic cells; and selecting for those cells that are Thy-1 − , IL-7Rα (CD127) − , and lineage panel − , to provide an enriched population of cells having myeloid progenitor activity.

13. The method according to claim 12 , wherein said lineage panel includes CD2; CD3; CD4; CD7; CD8; CD10; CD11b; CD14; CD19; CD20; CD56; and glycophorin A (GPA).

14. The method according to claim 12 , wherein said sample of hematopoietic cells is bone marrow.

15. The method according to claim 12 , wherein said sample of hematopoietic cells is mobilized peripheral blood.

16. The method of claim 3 , wherein said common myeloid progenitors are enriched by combining reagents that specifically recognize IL-3Rα, and CD45RA; and selecting for those cells that are IL-3Rα lo CD45RA − .

17. The method according to claim 8 , wherein said erythroid/megakaryocyte committed progenitor cells are enriched by combining reagents that specifically recognize IL-3Rα, and CD45RA; and selecting for those cells that are IL-3Rα − CD45RA − .

18. The method of claim 1 wherein the individual is immunocompromised.

19. The method of claim 1 wherein the individual is suffers from neutropenia.

20. The method of claim 1 wherein a population of administered cells comprises at least about 75% allogeneic myeloid progenitor cells.

21. The method of claim 1 wherein, wherein said myeloid progenitor cells comprise at least two Class I HLA mismatch relative to said individual.

22. The method of claim 1 wherein said myeloid progenitor cells comprise at least three Class I HLA mismatch relative to said individual.

23. The method of claim 1 wherein the biologically effective dose is at least 10 4 myeloid progenitor cells/kg body weight.

24. The method of claim 1 wherein the biologically effective dose is at least about 5×10 5 myeloid progenitor cells/kg body weight.

25. The method of claim 1 wherein the biologically effective dose is at least about 1×10 6 myeloid progenitor cells/kg body weight.

26. The method of claim 1 wherein the cells are administered parenterally.

27. The method of claim 1 wherein the cells are administered intravenously.

28. The method of claim 1 further comprising transplanting into said individual hematopoietic stem cells.

Assignees

• Brown Janice Marie
• Univ Leland Stanford Junior

Inventors

• Brown Janice Marie

Classifications

• A61K38/196

  Thrombopoietin · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K35/19

  Platelets; Megacaryocytes · CPC title

• A61K38/1816 Primary

  Erythropoietin [EPO] · CPC title

• A61K38/193 Primary

  Colony stimulating factors [CSF] · CPC title